Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR444200 in GPC3+ advanced solid tumors
NCT05450562Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Sep 2022
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies, Nanobodies (VHH), Fc-Fusion Proteins
- Countries
- 5
01
Overview
A Phase 2 trial of SAR444200 in hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), solid tumor, sponsored by Sanofi. Started Sep 2022; status: terminated.
02
Drugs
SAR444200
03
Conditions
hepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT05450562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05450562.